Global healthcare company Abbott (NYSE:ABT) announced on Monday the release of Libre Assist, a new feature within the Libre app.
Libre Assist is designed to help people living with diabetes in the US better understand how the foods they eat affect their glucose levels. Unlike traditional food logging apps that only give feedback after a meal is logged, Libre Assist is designed to help people make informed mealtime decisions before they eat.
Using generative artificial intelligence (AI), the feature illustrates the potential glucose impact of a food choice with a color-coded rating system -- green for minor, yellow for moderate, and orange for major.
Abbott is launching the new technology during CES 2026 in Las Vegas.
Renalytix expands US clinical footprint with three kidneyintelX.dkd integrations
Acousia Therapeutics completes patient enrolment in Phase 2 trial of Bimokalner
ZYUS Life Sciences reports positive preliminary results from Phase 2a trial of Trichomylin softgel
DELFI Diagnostics names new chief financial officer
Organon signs commercialisation agreement for Nilemdo across six European markets
Antin to acquire clinical trial equipment provider Emsere
Merck completes acquisition of Cidara Therapeutics for USD9.2bn
GSK wins European Commission approval for Shingrix prefilled syringe
GSK reports positive phase III results for bepirovirsen in chronic hepatitis B
Bambusa Therapeutics reports first patient dosed in proof-of-concept COPD trial
Day One completes Mersana acquisition to add rare cancer antibody drug conjugate